Evidence map›Paper›PMID 41939480›Full record

ArticleFrontiers in oncology2026

ELDA: real-time functional drug profiling in acute lymphoblastic leukemia.

Samara Sousa Mariano, Leandro Henrique de Paula Assis, Juliana Ronchi Correa, Rafael Renatino Canevarolo, Natacha Azussa Migita, Praneeth Reddy Sudalagunta, Amilcar Cardoso de Azevedo, João Meidanis, Silvia Regina Brandalise, Ariosto Siqueira Silva and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Samara Sousa MarianoLeukemia biology laboratory, Boldrini Children's Center, Campinas, Brazil.
Leandro Henrique de Paula AssisLeukemia biology laboratory, Boldrini Children's Center, Campinas, Brazil.
Juliana Ronchi CorreaLeukemia biology laboratory, Boldrini Children's Center, Campinas, Brazil.
Rafael Renatino CanevaroloDepartment of Metabolism and Physiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States.
Natacha Azussa MigitaLeukemia biology laboratory, Boldrini Children's Center, Campinas, Brazil.
Praneeth Reddy SudalaguntaDepartment of Metabolism and Physiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States.
Amilcar Cardoso de AzevedoLeukemia biology laboratory, Boldrini Children's Center, Campinas, Brazil.
João MeidanisInstitute of Computing, University of Campinas, Campinas, Brazil.
Silvia Regina BrandaliseLeukemia biology laboratory, Boldrini Children's Center, Campinas, Brazil.
Ariosto Siqueira SilvaDepartment of Metabolism and Physiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States.
José Andrés YunesLeukemia biology laboratory, Boldrini Children's Center, Campinas, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Pediatric acute lymphoblastic leukemia (ALL) has cure rates exceeding 80%, yet approximately 20% of patients experience relapse, for whom treatment remains challenging. The biological and clinical heterogeneity of ALL complicates therapeutic decision-making, especially in relapse. A functional, patient-specific tool to identify effective drugs could complement current stratification approaches and potentially optimize therapy selection. Methods: We developed ELDA ( Results and discussion: ELDA's results demonstrated strong concordance with established cytotoxicity assays, including MTT and Calcein-AM, validating its performance

Indexed as

acute lymphoblastic leukemiaex vivo drug screeningPDX modelspediatric leukemiatime-lapse microscopy

Identifiers

PMID41939480
PMCPMC13046488

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.